Mapping the correlations between CSF Abeta and tau and hippocampal atrophy in 282 ADNI subjects...
-
Upload
liliana-skinner -
Category
Documents
-
view
217 -
download
3
Transcript of Mapping the correlations between CSF Abeta and tau and hippocampal atrophy in 282 ADNI subjects...
Mapping the correlations between CSF Abeta and tau and hippocampal atrophy in 282 ADNI subjects
Liana G. Apostolova, Amity E. Green, Kristy S. Hwang,
Jonathan H. Morra, Jeffrey L. Cummings, Arthur W. Toga,
Clifford R. Jack Jr., John Q. Trojanowski, Leslie M. Shaw,
Michael W. Weiner, Paul Thompson
Disclosures
• This work was generously supported by – NIA K23 AG026803 (jointly sponsored by NIA, AFAR,
The John A. Hartford Foundation, The Atlantic Philanthropies, The Starr Foundation and an anonymous donor)
– UCLA ADRC NIA AG16570– The Kassel Parkinson’s Disease and the Turken
Foundations – The Easton Consortium
Background
• Cerebrospinal fluid (CSF) Abeta and tau are the most established and most promising fluid biomarkers in AD.
• Low Abeta and increased tau levels have consistently been reported in the CSF of AD subjects as well as those MCI subjects who progress to AD.
Frank RA et al., Neurobiol Aging 1998
Thal LJ et al, Alzheimer Dis Assoc Disord, 2006
Background cont.
• AD results in progressive hippocampal volume loss.
• Hippocampal atrophy is the most established imaging biomarker in AD.
• Advanced hippocampal atrophy in MCI is suggestive of underlying AD (OR for conversion to AD = 1.75)
Jack, 1999 and 2004
Objective:
• To investigate the associations between CSF Abeta and tau levels and hippocampal atrophy in the ADNI cohort at baseline
Subjects: Demographic Data
NCN=83
MCIN=140
ADN=59
p-value,ANOVA or Chi-Square
Age, yr 75.6 (5.3) 74.0 (7.3) 75.7 (7.9) 0.16
Gender, M:F 41:42 91:49 34:25 0.07
Education, yr 15.6 (2.9) 16.0 (3.0) 15.3 (3.2) 0.34
MMSE 29.1 (1.0) 26.9 (1.8) 23.4 (1.8) < 0.0001
Comparable to Shaw LM et al, Ann Neurol online pub
CSF Biomarker Analysis
• Multiplex xMAP Luminex platform
• Innogenetics immunoassay kit-based reagent with the following monoclonal antibodies (Ab)– 4D7A3 Ab for Abeta– AT120 Ab for total tau– AT270 Ab for pTau181p
• Day-to-day reproducibility showed less then 10% variation Shaw LM et al, Ann Neurol online pub
Mean CSF Biomarker Concentrations
Comparable to Shaw LM et al, Ann Neurol online pub
Automated Hippocampal Segmentation AdaBoost
Radial Distance Mapping
Mean Hippocampal Volumes
3D Abeta1-42 correlation maps
3D Tau correlation maps
3D pTau181p correlation maps
Volumetric vs. 3D radial distance associations with CSF biomarkers
Left Hippocampus,p-values
Right Hippocampus,p-values
Abeta1-42, pg/ml 0.023 0.003 0.008 0.0003
Tau, pg/ml 0.001 0.002 0.004 0.003
pTau181p, pg/ml 0.019 0.01 0.002 0.0008
Tau/Abeta1-42 <0.0001 0.0006 0.002 0.002
pTau181p/Abeta1-4 0.005 0.002 0.001 0.0007
Hippocampal volume
Hippocampal radial distance
Cumulative Distribution Function CSF biomarker association with 3D radial distance
DiscussionDiagnostic accuracy of premortem CSF biomarkers
BiomarkerThreshold value
ROC Sensitivity Specificity Diagnostic Accuracy
Abeta1-42
192 pg/ml0.91 96.4 76.9 87%
Tau 93 pg/ml
0.83 69.6 92.3 81%
pTau181p 23 pg/ml
0.75 67.9 73.1 70%
Tau/Abeta1-42
0.390.92 85.7 84.6 85%
pTau181p/Abeta1-42
0.10.86 91.1 71.2 82%
Shaw LM et al, Ann Neurol online pub
Summary• Hippocampal atrophy shows significant
correlations with CSF biomarkers in a study sample consisting of NC, MCI and AD
• 3D hippocampal surface maps show more significant associations with CSF biomarkers relative to hippocampal volumes
• Abeta, Tau/Abeta1-42 and pTau181p/Abeta1-4 show the strongest correlations with 3D maps of hippocampal atrophy
Future Directions
• Does progressive hippocampal atrophy associate with CSF biomarker changes?
• Would CSF biomarkers and hippocampal atrophy have an additive value for diagnosing early and presymptomatic AD?
• Can they be combined to sensitively track disease progression and therapeutic effects?